The nurse reports to the healthcare provider signs of increased intracranial pressure in an infant with myelomeningocele who has which finding?

Option A, "Fatigue," is a symptom of anemia but is not a long-term complication associated with Thalassemia major.

Option B, "Deferoxamine usage," is a treatment to manage iron overload and not a complication associated with Thalassemia major.

Option C, "Immunosuppressive therapy," is not typically used to manage Thalassemia major and is not a long-term complication but rather a potential treatment for certain cases of thalassemia.

Option D. Hemochromatosis/Hemosiderosis

Thalassemia major is a genetic disorder that results in the body's inability to produce enough hemoglobin, leading to severe anemia.

To manage this condition, frequent blood transfusions are required, which can lead to iron overload in the body. Excess iron gets deposited in various organs and tissues, causing damage.

Hemochromatosis or hemosiderosis is a condition characterized by the accumulation of iron in organs like the liver, heart, and endocrine glands, which can result from repeated blood transfusions.

The complications associated with iron overload include liver damage, heart problems, diabetes, and more. Treatment with iron chelating agents like deferoxamine is often necessary to remove excess iron from the body.

To calculate the number of tablets to administer, you need to convert the dose to micrograms (mcg) to match the tablet strength:

0.175 mg is equivalent to 175 mcg (since 1 mg = 1000 mcg).

Now, divide the required dose (175 mcg) by the strength of the available tablets (88 mcg/tablet):

175 mcg ÷ 88 mcg/tablet ≈ 1.9886

Rounding to the nearest whole number, you should administer 2 tablets per dose.